Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major uterine fibroids markets are expected to exhibit a CAGR of 2.99% during 2024-2034.
The uterine fibroids market has been comprehensively analyzed in IMARC's new report titled "Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Uterine fibroids, also known as leiomyomas, refer to noncancerous growths that develop in the muscular wall of the uterus (womb). Most women suffering from this ailment do not experience any symptoms. However, depending on their size, location, and number, fibroids can cause a range of indications, such as heavy or prolonged menstrual periods, pelvic pain or pressure, frequent urination, difficulty emptying the bladder completely, constipation, backache or leg pain, enlargement of the abdomen, pain during sexual intercourse, etc. In severe cases, patients may also experience infertility or recurrent miscarriages. The diagnosis of uterine fibroids is usually made through a combination of the patient's medical history, characteristic findings, and pelvic examination. Several other diagnostic procedures, including magnetic resonance imaging and transabdominal or transvaginal ultrasound, are also utilized for assessing the size and location of fibroids and determining their impact on surrounding structures. The healthcare provider may further perform hysterosalpingography, which involves injecting a contrast dye into the uterus and fallopian tubes to detect submucosal fibroids and evaluate the patency of the fallopian tubes.
The rising cases of hormonal imbalances, which can disrupt the normal balance between estrogen and progesterone, are primarily driving the uterine fibroids market. In addition to this, the increasing incidences of several risk factors, including early onset of menstruation, nulliparity, high intake of red meat, genetic predisposition, obesity, etc., are also bolstering the market growth. Furthermore, the widespread adoption of levonorgestrel-releasing intrauterine devices (IUDs), since they can help to control heavy bleeding associated with the disease and provide symptomatic relief in women, is acting as another significant growth-inducing factor. Apart from this, the escalating demand for gonadotropin-releasing hormone (GnRH) agonists, which work by suppressing the production of estrogen and progesterone, thereby reducing the size of fibroids and inducing a temporary state of menopause, is also creating a positive outlook for the market. Moreover, the inflating utilization of magnetic resonance-guided focused ultrasound surgery, a noninvasive procedure that uses ultrasound waves to heat and destroy abnormal tissue without incisions, is expected to drive the uterine fibroids market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the uterine fibroids market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for uterine fibroids and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the uterine fibroids market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the uterine fibroids market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the uterine fibroids market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current uterine fibroids marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the uterine fibroids market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the uterine fibroids market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the uterine fibroids market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of uterine fibroids across the seven major markets?
What is the number of prevalent cases (2018-2034) of uterine fibroids by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of uterine fibroids by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with uterine fibroids across the seven major markets?
What is the size of the uterine fibroids patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of uterine fibroids?
What will be the growth rate of patients across the seven major markets?
Uterine Fibroids: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for uterine fibroids drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the uterine fibroids market?
What are the key regulatory events related to the uterine fibroids market?
What is the structure of clinical trial landscape by status related to the uterine fibroids market?
What is the structure of clinical trial landscape by phase related to the uterine fibroids market?
What is the structure of clinical trial landscape by route of administration related to the uterine fibroids market?
The uterine fibroids market has been comprehensively analyzed in IMARC's new report titled "Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Uterine fibroids, also known as leiomyomas, refer to noncancerous growths that develop in the muscular wall of the uterus (womb). Most women suffering from this ailment do not experience any symptoms. However, depending on their size, location, and number, fibroids can cause a range of indications, such as heavy or prolonged menstrual periods, pelvic pain or pressure, frequent urination, difficulty emptying the bladder completely, constipation, backache or leg pain, enlargement of the abdomen, pain during sexual intercourse, etc. In severe cases, patients may also experience infertility or recurrent miscarriages. The diagnosis of uterine fibroids is usually made through a combination of the patient's medical history, characteristic findings, and pelvic examination. Several other diagnostic procedures, including magnetic resonance imaging and transabdominal or transvaginal ultrasound, are also utilized for assessing the size and location of fibroids and determining their impact on surrounding structures. The healthcare provider may further perform hysterosalpingography, which involves injecting a contrast dye into the uterus and fallopian tubes to detect submucosal fibroids and evaluate the patency of the fallopian tubes.
The rising cases of hormonal imbalances, which can disrupt the normal balance between estrogen and progesterone, are primarily driving the uterine fibroids market. In addition to this, the increasing incidences of several risk factors, including early onset of menstruation, nulliparity, high intake of red meat, genetic predisposition, obesity, etc., are also bolstering the market growth. Furthermore, the widespread adoption of levonorgestrel-releasing intrauterine devices (IUDs), since they can help to control heavy bleeding associated with the disease and provide symptomatic relief in women, is acting as another significant growth-inducing factor. Apart from this, the escalating demand for gonadotropin-releasing hormone (GnRH) agonists, which work by suppressing the production of estrogen and progesterone, thereby reducing the size of fibroids and inducing a temporary state of menopause, is also creating a positive outlook for the market. Moreover, the inflating utilization of magnetic resonance-guided focused ultrasound surgery, a noninvasive procedure that uses ultrasound waves to heat and destroy abnormal tissue without incisions, is expected to drive the uterine fibroids market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the uterine fibroids market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for uterine fibroids and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the uterine fibroids market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the uterine fibroids market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the uterine fibroids market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current uterine fibroids marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the uterine fibroids market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the uterine fibroids market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the uterine fibroids market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of uterine fibroids across the seven major markets?
What is the number of prevalent cases (2018-2034) of uterine fibroids by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of uterine fibroids by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with uterine fibroids across the seven major markets?
What is the size of the uterine fibroids patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of uterine fibroids?
What will be the growth rate of patients across the seven major markets?
Uterine Fibroids: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for uterine fibroids drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the uterine fibroids market?
What are the key regulatory events related to the uterine fibroids market?
What is the structure of clinical trial landscape by status related to the uterine fibroids market?
What is the structure of clinical trial landscape by phase related to the uterine fibroids market?
What is the structure of clinical trial landscape by route of administration related to the uterine fibroids market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 UTERINE FIBROIDS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 UTERINE FIBROIDS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 UTERINE FIBROIDS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 UTERINE FIBROIDS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 UTERINE FIBROIDS - UNMET NEEDS
10 UTERINE FIBROIDS - KEY ENDPOINTS OF TREATMENT
11 UTERINE FIBROIDS - MARKETED PRODUCTS
11.1 List of Uterine Fibroids Marketed Drugs Across the Top 7 Markets
11.1.1 Lupron Depot (Leuprorelin depot) - AbbVie/Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Myfembree (Estradiol/norethisterone acetate/relugolix) - Myovant Sciences
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 UTERINE FIBROIDS - PIPELINE DRUGS
12.1 List of Uterine Fibroids Pipeline Drugs Across the Top 7 Markets
12.1.1 Vilaprisan - Bayer HealthCare Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Relugolix - Myovant/Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 KLH2109 - Kissei Pharmaceutical/ObsEva
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Elagolix - Abbvie/Neurocrine Biosciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. UTERINE FIBROIDS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. UTERINE FIBROIDS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 UTERINE FIBROIDS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Uterine Fibroids - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Uterine Fibroids - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Uterine Fibroids - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Uterine Fibroids - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Uterine Fibroids - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Uterine Fibroids - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Uterine Fibroids - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Uterine Fibroids - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Uterine Fibroids - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Uterine Fibroids - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Uterine Fibroids - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Uterine Fibroids - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Uterine Fibroids - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Uterine Fibroids - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Uterine Fibroids - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Uterine Fibroids - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Uterine Fibroids - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Uterine Fibroids - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Uterine Fibroids - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Uterine Fibroids - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Uterine Fibroids - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Uterine Fibroids - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Uterine Fibroids - Access and Reimbursement Overview
16 UTERINE FIBROIDS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 UTERINE FIBROIDS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 UTERINE FIBROIDS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 UTERINE FIBROIDS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 UTERINE FIBROIDS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 UTERINE FIBROIDS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 UTERINE FIBROIDS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 UTERINE FIBROIDS - UNMET NEEDS
10 UTERINE FIBROIDS - KEY ENDPOINTS OF TREATMENT
11 UTERINE FIBROIDS - MARKETED PRODUCTS
11.1 List of Uterine Fibroids Marketed Drugs Across the Top 7 Markets
11.1.1 Lupron Depot (Leuprorelin depot) - AbbVie/Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Myfembree (Estradiol/norethisterone acetate/relugolix) - Myovant Sciences
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 UTERINE FIBROIDS - PIPELINE DRUGS
12.1 List of Uterine Fibroids Pipeline Drugs Across the Top 7 Markets
12.1.1 Vilaprisan - Bayer HealthCare Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Relugolix - Myovant/Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 KLH2109 - Kissei Pharmaceutical/ObsEva
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Elagolix - Abbvie/Neurocrine Biosciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. UTERINE FIBROIDS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. UTERINE FIBROIDS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 UTERINE FIBROIDS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Uterine Fibroids - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Uterine Fibroids - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Uterine Fibroids - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Uterine Fibroids - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Uterine Fibroids - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Uterine Fibroids - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Uterine Fibroids - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Uterine Fibroids - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Uterine Fibroids - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Uterine Fibroids - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Uterine Fibroids - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Uterine Fibroids - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Uterine Fibroids - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Uterine Fibroids - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Uterine Fibroids - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Uterine Fibroids - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Uterine Fibroids - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Uterine Fibroids - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Uterine Fibroids - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Uterine Fibroids - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Uterine Fibroids - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Uterine Fibroids - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Uterine Fibroids - Access and Reimbursement Overview
16 UTERINE FIBROIDS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 UTERINE FIBROIDS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 UTERINE FIBROIDS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
